Novartis reported a 4% fall in sales in the second quarter as the coronavirus pandemic depressed business activity, particularly for the company’s ophthalmology business. But sales are expected to recover in the second half, giving a mid single-digit increase at constant currencies for the year as a whole, the company announced on 21 July.
